Risk-Reducing Surgery Improves Survival Outcomes in Younger BRCA+ Breast Cancer
Risk-reducing surgery improved survival outcomes in younger patients with breast cancer and a germline BRCA mutation.
Related Articles
NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET
NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.
Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma
Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
Designing Trials and Fueling Collaboration in Oncology: With D. Ross Camidge, MD, PhD; and Mary Redman, PhD
Drs Camidge and Redman discuss Dr Redman’s role as a biostatistician at Fred Hutch, outlining her work in designing clinical trials.
An Overview of the Treatment Landscape for EGFR-mutated NSCLC
A panelist discusses how EGFR-mutated NSCLC treatment has evolved to include multiple generations of EGFR tyrosine kinase inhibitors as first-line therapy, with newer agents showing…
2024 Year in Pictures
The past year has been marked by exceptional achievements and inspiring moments, many captured by our photographers. We’ve collected pictures and stories from throughout 2024.
Clive Peedell (@drpeedell.bsky.social)
Consultant Clinical Oncologist NHS advocate and campaigner Politically centre left Wealth inequality creates health inequality
Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma
Isa-RVd given as induction treatment without consolidation led to a 30% reduction in the risk of disease progression or death vs RVd in multiple myeloma.
36 chief innovation officers to know | 2024
Becker’s Healthcare is proud to spotlight 36 trailblazing chief innovation officers from hospitals and health systems across the nation.
Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid Tumors
A phase 1 trial of pembrolizumab plus denileukin diftitox shows 27% response and 33% clinical benefit in recurrent solid tumors, with manageable toxicity.